NKTR Stock Analysis: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$71.04
6.65 (10.33%)
▲
5d:
+14.53%
30d:
+21.31%
90d:
-6.17%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 6.0/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: NKTR is 8.3% above its trading range ($65.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: NKTR is 8.3% above its trading range ($65.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $71.04, which is considered slightly high relative to its 30-day fair value range of $58.49 to $65.60.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is approaching resistance at $71.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.3% recently.
Market Sentiment: NKTR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $153.25 (+115.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is approaching resistance at $71.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.3% recently.
Market Sentiment: NKTR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $153.25 (+115.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$58.49 -
$65.60
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.3%)
- BULLISH: Trading 115.7% below Wall St target ($153.25)
- CAUTION: Extended 8.3% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$58.49 -
$65.60
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$59.31
Resistance Level
$71.50
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.65
Wall Street Target
$153.25
(+115.7%)
Revenue Growth (YoY)
3.8%
Profit Margin
-284.2%
Share & Embed Analysis
Last updated: July 04, 2026 4:57 PM ET
Data refreshes hourly during market hours. Next update: 5:57 PM
Data refreshes hourly during market hours. Next update: 5:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Zalevsky
SELL
180 shares
2026-02-18
Howard W Robin
SELL
423 shares
2026-02-18
Jonathan Zalevsky
SELL
3867 shares
2026-01-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
